DGAP-News: NEOVACS ANNOUNCES CLOSING OF 7.5M EURO CAPITAL INCREASE WITH U.S. INSTITUTIONAL INVESTORS


DGAP-News: Neovacs S.A. / Key word(s): Capital Increase
NEOVACS ANNOUNCES CLOSING OF 7.5M EURO CAPITAL INCREASE WITH U.S.
INSTITUTIONAL INVESTORS

02.07.2015 / 08:00

---------------------------------------------------------------------

PRESS RELEASE

NEOVACS ANNOUNCES CLOSING OF 7.5M EURO CAPITAL INCREASE WITH U.S.
INSTITUTIONAL INVESTORS
 

Paris and Boston, July 2, 2015 - Neovacs (Alternext Paris: ALNEV), (the
"Company") a leader in active immunotherapies for the treatment of
autoimmune diseases, today announced the successful closing of the 7.5
million euros share capital increase subscribed by U.S. institutional
investors on June 25, 2015.

Following this transaction, Neovacs' share capital totals 4,808,446.50
euros divided into 32,056,310 shares, representing a dilution of 23.40% for
existing shareholders.

The proceeds of the capital increase will provide additional funding to the
Company to finance the development plan of IFNα-Kinoid, including:

  - A phase IIb clinical trial of IFNα-Kinoid in lupus conducted in Europe,
    Latin America and Asia, to begin in the second half of 2015; and

  - A phase IIa clinical trial of IFNα-Kinoid in lupus conducted in the
    United States. This study is expected to begin six months after
    initiation of the phase IIb clinical trial of IFNα-Kinoid, and will
    provide additional, U.S.-specific, data to the results previously
    obtained in Europe[1].

Maxim Group LLC acted as sole placement agent in connection with the
capital increase.

[1] Results of a Phase I/II clinical trial of IFNα-Kinoid were published in
November 2011 at ACR and published in 2013 in Rheumatoid & Arthritis
(Lauwerys, 2013)


About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus and dermatomyositis. Neovacs is
also conducting preclinical development works on other therapeutic vaccines
in the fields of auto-immune diseases, oncology and allergies. The goal of
the Kinoid approach is to enable patients to have access to safe treatments
with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

Contacts 
    
NEOVACS - Investor Relations
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com

Investor Relations / Financial Communications - NewCap 
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
theradiag@newcap.fr

Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu


Disclaimer

This announcement is for information purposes only. It does not, and shall
not, in any circumstances, constitute a public offering of securities by
Neovacs nor a solicitation of an offer to subscribe for securities in any
jurisdiction, including France.

In accordance with Article 211-3 of the General Regulation of the French
Financial Market Authority (AMF), the capital increase does not require a
prospectus to be submitted for approval to the AMF.

The securities referred to herein have not been and will not be registered
under the U.S. Securities Act of 1933, as amended (the "U.S. Securities
Act"), and the securities may not be offered or sold in the United States
unless these securities are registered under the U.S. Securities Act, or an
exemption from the registration requirements of the U.S. Securities Act is
available. The Company and its affiliates have not registered, and do not
intend to register, any portion of the securities concerned in the United
States, and do not intend to conduct a public offering of securities in the
United States.

With respect to the member states of the European Economic Area which have
implemented the Directive 2003/71/EC of the European Parliament and the
Council of November 4, 2003, as amended, in particular by Directive
2010/73/EC of the European Parliament and of the Council of November 24,
2010 (the "Prospectus Directive"), no action has been undertaken or will be
undertaken to make an offer to the public of the securities referred to
herein requiring a publication of a prospectus in any relevant member
state. In addition, in the United Kingdom, this announcement is being
distributed only to, and is directed only at, qualified investors (i) who
have professional experience in matters relating to investments falling
within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the "Order") and qualified
investors falling within Article 49(2)(a) to (d) of the Order, and (ii) to
whom it may otherwise lawfully be communicated (all such persons together
being referred to as "relevant persons"). The offering will only be
available to, and any invitation, offer or agreement to subscribe for,
purchase, or otherwise acquire securities will be engaged in only with
relevant persons. Any person who is not a relevant person should not act or
rely on this announcement or any of its contents.

The distribution of this announcement in certain countries may be subject
to specific regulations. The persons in possession of this announcement
shall then get knowledge of any local restrictions and shall comply with
these restrictions.

THIS DOCUMENT MAY NOT BE PUBLISHED, DISTRIBUTED OR DISSEMINATED, DIRECTLY
OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN,
SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT WOULD BE PROHIBITED BY LAW



---------------------------------------------------------------------

02.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                   
Company:     Neovacs S.A.                                              
             3-5, Impasse Reille                                       
             75014 Paris                                               
             France                                                    
Phone:       +33 (0)1 53 10 93 00                                      
Fax:         +33 (0)1 53 10 93 03                                      
E-mail:      www.neovacs.fr                                            
Internet:    info@neovacs.fr                                           
ISIN:        FR0004032746                                              
WKN:         A1CVKR                                                    
Listed:      Regulated Unofficial Market in Stuttgart; Open Market in  
             Frankfurt                                                 
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
374443 02.07.2015